Use of remdesivir for COVID-19 in patients with hematologic cancer

被引:0
作者
Alexandra Martin-Onraët
Corazón Barrientos-Flores
Diana Vilar-Compte
Carolina Pérez-Jimenez
Pamela Alatorre-Fernandez
机构
[1] Instituto Nacional de Cancerología,Infectious Diseases Department
来源
Clinical and Experimental Medicine | 2023年 / 23卷
关键词
Remdesivir; COVID-19; Hematologic malignancies; Omicron;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2231 / 2238
页数:7
相关论文
共 170 条
[1]  
Nyberg T(2022)Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study Lancet Lond Engl 399 1303-1312
[2]  
Ferguson NM(2022)Attenuated replication and pathogenicity of SARS-CoV-2 B11529 Omicron Nature 603 693-699
[3]  
Nash SG(2022)SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells Emerg Microbes Infect 11 277-283
[4]  
Webster HH(2020)Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study The Lancet 395 1907-1918
[5]  
Flaxman S(2022)Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave Cancer Cell 40 343-345
[6]  
Andrews N(2022)Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis BMJ Open 12 340-346
[7]  
Shuai H(2022)COVID-19 vaccination and breakthrough infections in patients with cancer Ann Oncol Off J Eur Soc Med Oncol 33 54-1878
[8]  
Chan JFW(2022)SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders J Hematol OncolJ Hematol Oncol 15 16-875
[9]  
Hu B(2021)Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients MedRxiv Prepr Serv Health Sci. 11 1877-E317
[10]  
Chai Y(2022)Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies Ann Hematol 101 865-446